Association of Neutrophil-to-Lymphocyte Ratio With Efficacy of First-Line Avelumab Plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Mehmet Asim BilenBrian I RiniMartin H VossJames LarkinJohn B A G HaanenLaurence AlbigesLance C PagliaroEric G VoogElaine T LamNikolay KislovBradley Alexander McGregorAly-Khan A LalaniBo HuangAlessandra di PietroStan KrulewiczPaul B RobbinsToni K ChoueiriPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Current data support NLR as a prognostic biomarker in patients with advanced RCC receiving avelumab plus axitinib or sunitinib.